Premium
Clorgyline, a Monoamine oxidase‐A Inhibitor, Protects from Neointima Formation in Rat Carotid Artery Angioplasty Model
Author(s) -
JIEYU WANG
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.1201.12
Subject(s) - restenosis , neointima , clorgyline , neointimal hyperplasia , monoamine oxidase , medicine , angioplasty , coronary arteries , cell growth , serotonin , endocrinology , artery , pharmacology , chemistry , cardiology , stent , biochemistry , enzyme , receptor
Percutaneous Transluminal Coronary Angioplasty (PTCA) is a clinical technique used to reopen the arteries of the heart (coronary arteries) narrowed or blocked. Restenosis, a common surgical complication of PTCA, was characterized as the proliferation and the migration of vascular smooth muscle cells (VSMCs). Serotonin (5‐hydroxytryptamine; 5‐HT) is a mitogen for VSMCs, which may contribute to the progression of neointimal proliferation after angioplasty. Monoamine oxidases (MAOs), the critical enzymes to involve serotonin metabolism, can increase the reactive oxygen species to stimulate cell proliferation. The purpose of this study was to understand the potential pathological roles of serotonin and monoamine oxidase in the development of neointimal hyperplasia (or restenosis). Cell proliferation and migration were examined by MTT and Wound‐healing assays, respectively. The protein expressions were monitored by Western blotting. Experimental data showed that the MAO‐A inhibitor, clorgyline, rather than the MAO‐B inhibitor, selegiline, can significantly reduce 1% FBS‐stimulated VSMC growth. Accordingly, clorgyline was further evaluated in rat carotid artery angioplasty model, and histopathological results suggested that MAO‐A expression was obviously up‐regulated within injured artery and neointima formation can be markedly reduced by clorgyline. This potentially implicates MAO‐A inhibitor could be a potential application for restenosis prevention. Support or Funding InformationExpression difference of two MAOs in the artery.Effect of MAO‐A inhibitors in 1% FBS‐stimulated VSMC proliferation.** P < 0.01 compared to the group treated with 1% FBS alone.Inhibitory effect of MAO‐A inhibitor on preventing neointimal hyperplasia in rat model.